Abstract
The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.
Original language | English |
---|---|
Pages (from-to) | 356-359 |
Number of pages | 4 |
Journal | Cancer Chemotherapy and Pharmacology |
Volume | 36 |
Issue number | 4 |
DOIs | |
Publication status | Published - Jul 1995 |
Keywords
- Bioequivalence
- Megestrol acetate
- Pharmacokinetics
ASJC Scopus subject areas
- Pharmacology
- Oncology
- Cancer Research